A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML

Jonathan A Webster,Tara M Robinson,Amanda L Blackford,Erica Warlick,Anna Ferguson,Ivan Borrello,Marianna Zahurak,Richard J Jones,B Douglas Smith

Leukemia Research（2021）

引用 4|浏览23

暂无评分

摘要

•Adjuvant interferon-α/GM-CSF and K562/G-CSF vaccine were safe with TKIs.•Patients more frequently discontinued interferon-α/GM-CSF due to side effects.•Adjuvant interferon-α/GM-CSF more frequently led to undetectable BCR-ABL PCR.•36.4 % of patients sustained treatment-free remission after interferon-α/GM-CSF.

查看译文

关键词

Immunotherapy,Imatinib,TKI discontinuation,Chronic myeloid leukemia,Randomized trial,Vaccine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要